The Correlation Between Lymphocyte Nadir and Radiation Therapy for Soft Tissue Sarcoma: Defining Key Dosimetric Parameters and Outlining Clinical Significance.


Journal

Advances in radiation oncology
ISSN: 2452-1094
Titre abrégé: Adv Radiat Oncol
Pays: United States
ID NLM: 101677247

Informations de publication

Date de publication:
Jan 2024
Historique:
received: 06 04 2023
accepted: 28 06 2023
medline: 23 1 2024
pubmed: 23 1 2024
entrez: 23 1 2024
Statut: epublish

Résumé

The objectives of this study were to identify key dosimetric parameters associated with postradiation therapy lymphopenia and uncover any effect on clinical outcomes. This was a retrospective review of 69 patients (between April 2010 and January 2023) who underwent radiation therapy (RT) as a part of curative intent for soft tissue sarcoma (STS) at a single academic institution. All patients with treatment plans available to review and measurable absolute lymphocyte count (ALC) nadir within a year after completion of RT were included. Median follow-up was 22 months after the start of RT. A decrease in lymphocyte count was noted as early as during treatment and persisted at least 3 months after the completion of RT. On multivariable linear regression, the strongest correlations with ALC nadir were mean body dose, body V10 Gy, mean bone dose, bone V10 Gy, and bone V20 Gy. Five-year overall survival was 60% and 5-year disease-free survival was 44%. Advanced T-stage, chemotherapy use, use of intensity-modulated RT, lower ALC nadir, and the development of grade ≥2 lymphopenia at nadir were associated with worse overall survival and disease-free survival. Post-RT lymphopenia was associated with worse outcomes in STS. There were associations between higher body V10 Gy and bone V10 Gy and lower post-RT ALC nadir, despite the varying sites of STS presentation, which aligns with the well-known radiosensitivity of lymphocyte cell lines. These findings support efforts to reduce treatment-related hematopoietic toxicity as a way to improve oncologic outcomes. Additionally, this study supports the idea that the effect of radiation on lymphocyte progenitors in the bone marrow is more significant than that on circulating lymphocytes in treatments with limited involvement of the heart and lung.

Identifiants

pubmed: 38260229
doi: 10.1016/j.adro.2023.101309
pii: S2452-1094(23)00137-9
pmc: PMC10801664
doi:

Types de publication

Journal Article

Langues

eng

Pagination

101309

Informations de copyright

© 2023 The Author(s).

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Eric Ku (E)

Department of Radiation Oncology, University of California, Irvine, Orange, California.

Garrett Harada (G)

Department of Radiation Oncology, University of California, Irvine, Orange, California.

Elaine Chiao (E)

School of Medicine, University of California, Irvine, Irvine, California.

Pranathi Rao (P)

School of Medicine, University of California, Irvine, Irvine, California.

Sina Hosseinian (S)

School of Medicine, University of California, Irvine, Irvine, California.

Steven Seyedin (S)

Department of Radiation Oncology, University of California, Irvine, Orange, California.

Erin Healy (E)

Department of Radiation Oncology, University of California, Irvine, Orange, California.

Peter Maxim (P)

Department of Radiation Oncology, University of California, Irvine, Orange, California.

Warren Chow (W)

Department of Hematology/Oncology, University of California, Irvine, Orange, California.

Russell Stitzlein (R)

Orthopedic Surgery, University of California, Irvine, Orange, California.

Charles Limoli (C)

Department of Radiation Oncology, University of California, Irvine, Orange, California.

Jeremy Harris (J)

Department of Radiation Oncology, University of California, Irvine, Orange, California.

Classifications MeSH